Join the Granulomatosis with Polyangiitis group to help and get support from people like you.
Granulomatosis with Polyangiitis News
Related terms: Wegener's Granulomatosis
Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis
18 September 2024 – AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, im...
FDA Approves Tavneos (avacopan) for the Adjunctive Treatment of ANCA-Associated Vasculitis
First FDA-approved orally-administered inhibitor of the complement 5a receptor SAN CARLOS, Calif., Oct. 08, 2021 (GLOBE NEWSWIRE) – ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S....
FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan
THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to...
FDA Approves Rituxan (rituximab) for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in Children
South San Francisco, CA – September 27, 2019 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan
July 23, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab),1 for the treatment...